Gino. Simple answer is NO!. The reasons for selling are exactly...

Gino. Simple answer is NO!. The reasons for selling are exactly what the company disclosed..No conspiracies or hidden agendas.

In fact any possible license deal is much easier to do if the FDA approved manufacturing has been sorted. Especially in the very constrained CELL THERAPY manufacturing area.

This is a brilliant deal. Adding in the ATO R&D rebate which came through any day takes IMU over $150m cash again with supply of product sorted.

The company has announced that the drug needed for the next Azer-Cel trial is on the shelf ready to go.

They haven’t clearly stated but would be good to know there is sufficient supply for the Azer-Cel. ONCARLYTICS trial. This trial will be groundbreaking. By then we might be at OBD for Oncarlytics. Added to a likely Worlds First Allogenic CarT CD19 targeting drug.

This of course won’t attract any attention in Oz , you can be sure the people that matter in the US will have front row seats.

This technology could totally disrupt the CarT market affecting over 500 companies.
If this works it will disrupt the 100% cancer market. Thats hot and cold cancers. Over a century ago HOT diseases killed the most people..All those are infectious diseases. Vaccines and antibiotics etc cleared these diseases away.

Only to be replaced by COLD diseases. Modern scientific advances beat HOT diseases. A huge advancement for mankind. And a contributing factor to the population explosion.

The good news is the science is about to conquer cold diseases are about to be beaten. And the company that is about to slay this beast is IMUGENE.

All we need to do is sit. Just buy as much as you can afford and sit. We are now following a well beaten path to disrupting the status quo.

The biggest advances in history come from combined two seperate technologies. Like the wheel and the horse, then the wheel and the steam engine, the wheel and the combustion engine. The wheel Combustion engine and aeronautical design.

CF33 is and updated genetically altered old technology paired with Allogenic CarT a new therapy. It’s relatively cheap. It’s applies to a global market.. It’s easily distributed. And is got 15 years of protection from competition.

And it’s run by experts who are driven to win this race. Leslie Chong and Yuman Fong will prove to be one of the greatest teams ever.

Watch this space!